期刊文献+

伊布利特对人体心房与心室电生理特性的影响

The Study of Atrium and Ventricle Electrophysiological Effect of Ibutilide on Human.
下载PDF
导出
摘要 探讨伊布利特对人体右房、左房及右室有效不应期(RA-ERP、LA-ERP及RV-ERP)与房间、室间传导时间的影响。测定25例射频消融术后患者于静脉推注伊布利特(0.0167mg/kg)前后在基础起搏周长为600ms时的RA-ERP、LA-ERP及RV-ERP,同时测量起搏与窦性心律时的心房、心室传导时间。其中通过起搏冠状静脉窦远端间接起搏左房。结果:①伊布利特明显延长RA-ERP、LA-ERP及RV-ERP(P均<0.001)。②使用伊布利特后,对窦性心律时的P波宽度、PR间期、QRS时限、AH及HV均无明显影响(P>0.05),对房间及室间传导时间无明显影响(P>0.05),亦对急性期的起搏阈值无明显影响(P>0.05)。③使用伊布利特后2例出现右束支阻滞。结论:伊布利特可明显延长RA-ERP、LA-ERP及RV-ERP,但不影响房间、室间传导时间。 We studied the effect of ibutilide on the electrophysiological parameters of human atrium and ventricle to explore the mechanism of ibutilide in Converting atrial fibrillation to sinus rhythm. Effective refractory period of left atrium, right atrium and right ventricular ( RA-ERP, LA-ERP, and RV-ERP) during pacing at cycle length of 600 ms, intra-atrial conduction time (IACT) and intra-ventricular conduction time (IVCT) were measured before and after intravenous administration of ibutilide (0. 0167 mg/kg) in 25 patients who underwent radiofrequency catheter ablation successfully. Results:(1) Ibutilide prolonged RA-ERP, LA-ERP, and RV-ERP (all P 〈 0.001 ). (2) The differences of P wave duration, PR interval, QRS duration, AH interval and HV interval at sinus rhythm before and after the administration of ibutilide weren't significant (all P 〉 0.05 ). When the pacing cycle length was 600 ms, IACT and IVCT did not change significantly either by ibutilide( all P 〉 0.05 ). (3) 2 patients developed complete right bundle branch block. Conclusions: Ibutilide prolongs RA-ERP, LA-ERP, and RV-ERP, but it does not affect IACT, IVCT. [ Chinese Journal of Cardiac Pacing and Electrophysiology,2005,19 (5) :335 - 337 ]
出处 《中国心脏起搏与心电生理杂志》 2005年第5期335-337,共3页 Chinese Journal of Cardiac Pacing and Electrophysiology
关键词 电生理学 伊布利特 有效不应期 传导时间 人体 Electrophysiology Ibutilide Effective refractory period Conduction time Human
  • 相关文献

参考文献1

二级参考文献20

  • 1Naccarelli GV,Lee KS,Gibson JK,et al.Electrophysiology and pharmacology of ibutilide.Am J Cardiol,1996,78:12-16.
  • 2Lych JR,Baskin EP,Nutt EM,et al.Comparison of binding to rapidly activating delayed rectifier K channel,Ikr and effects on myocardial refractoriness for class Ⅲ antiarrythmic agents.J Cardiovasc Pharmacol,1995,25:336-340.
  • 3Baskin EP,Lynch JJ Jr.Differential atrial versus ventricular activities of class Ⅲ potassium channel blockers.Pharmacol Exp Ther,1998,285:135-142.
  • 4Stambler BS,Beckman KJ,Kardish AH,et al.Acute hemodynamic effects of intravenous Ibutilide in patients with or without reduced left ventricular function.Am J Cardiol,1997,80:458- 463.
  • 5Stambler BS,Wood MA,Ellenbogen KA,et al.Antiarrhymic actions of intravenous Ibutilide compared with procaimamide during human atrial flutter and fibrillation:electrophysilogical determinants of enhanced conversion efficacy.Circulation,1997,96,4298- 4306.
  • 6Volgman AS,Stambler BS,Kappagoda C,et al.Comparison of intravenous Ibutilide versus procainainamide for rapid termination of atrial flutter or fibrillation.PACE,1996,19:608.
  • 7Kannel WB,Abbott RD,Savage DD,et al.Epidemiologic features of chronic atrial fibrillation:the Framingham study.N Engl J Med,1982,306:1018-1022.
  • 8Wijffels MECF,Kirchof CJHJ,Dorland R,et al.Atrial fibrillation begets atrial fibrillation.A study in awake chronically instrumented goats.Circulation,1995,92:1954-1968.
  • 9Cropp JS,Antal EG,Talbert RL,et al.Ibutilide:a new class Ⅲ antiarrhythmic agent.Parmarcotherapy,1997,17:1-9.
  • 10Vos MA,Golitsyn SR,Stangl K,et al.Superiority of ibutilide (a new class Ⅲ agent) over DL-sotalol in converting atrial flutter and atrial fibrillation.Heart,1998,79:568-575.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部